$230M Series C for first vision-restoring BCI
2026-03Science Corporation
Science closed an oversubscribed $230M Series C (total ~$490M) to commercialize PRIMA — a retinal BCI that restored form vision in dry-AMD patients (NEJM-published). A European launch later this year would make it the first BCI vision product on the market.